Alimta 100 mg/4mL (Pemetrexed disodium INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 100 mg/4mL

Alimta 100 mg/4mL is a lyophilized powder for solution, containing pemetrexed disodium. This medication is used in cancer treatment protocols. Learn more about its uses and effects.

Strength

100 mg/4mL

Pack Size

1 VIAL in 1 CARTON (0002-7640-01) / 4 mL in 1 VIAL

Manufacturer / TM Owner

Eli Lilly and Company

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Alimta 100 mg/4mL is primarily used in combination with other drugs for the treatment of certain types of cancer. Pemetrexed disodium, the active ingredient, is often part of chemotherapy regimens. Patients may wonder, 'What is Alimta used for?' It is typically administered intravenously as part of a broader treatment plan.

Side Effects

Common effects of Alimta 100 mg/4mL may include fatigue, nausea, and decreased appetite. Some patients may experience skin reactions at the injection site. These effects can vary widely among individuals and should be discussed with a healthcare provider.

Precautions & Warnings

Alimta 100 mg/4mL should be handled with care, as it is a potent medication. It is important to follow proper storage and administration guidelines. Patients should inform their healthcare provider about any allergies or medical conditions before starting treatment.

Avoid Interactions

Alimta 100 mg/4mL may interact with certain medications, including those that affect the immune system or other chemotherapy drugs. Alcohol and certain supplements may also interact with pemetrexed disodium. Always consult a healthcare provider before combining treatments.

Frequently Asked Questions

Alimta is used in combination with other drugs for the treatment of certain types of cancer.

Alimta is administered intravenously as a solution prepared from the lyophilized powder.

Common side effects may include fatigue, nausea, and skin reactions at the injection site.

Alimta may interact with certain medications, so it is important to consult a healthcare provider before combining treatments.

Patients should inform their healthcare provider about any allergies or medical conditions before starting Alimta treatment.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.